| Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non–small cell lung cancer: results of the … WSME Theelen, HMU Peulen, F Lalezari, V van der Noort, JF De Vries, ... JAMA oncology 5 (9), 1276-1282, 2019 | 809 | 2019 |
| Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma J Quispel-Janssen, V van der Noort, JF de Vries, M Zimmerman, ... Journal of Thoracic Oncology 13 (10), 1569-1576, 2018 | 252 | 2018 |
| Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial MJ Disselhorst, J Quispel-Janssen, F Lalezari, K Monkhorst, JF de Vries, ... The Lancet Respiratory Medicine 7 (3), 260-270, 2019 | 230 | 2019 |
| Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold DW Vredevoogd, T Kuilman, MA Ligtenberg, J Boshuizen, KE Stecker, ... Cell 178 (3), 585-599. e15, 2019 | 192 | 2019 |
| Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone … S Badrising, V van der Noort, IM van Oort, HP van den Berg, M Los, ... Cancer 120 (7), 968-975, 2014 | 159 | 2014 |
| Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma JL Vos, JBW Elbers, O Krijgsman, JJH Traets, X Qiao, AM van der Leun, ... Nature communications 12 (1), 7348, 2021 | 154 | 2021 |
| Prophylactic cranial irradiation versus observation in radically treated stage III non–small-cell lung cancer: a randomized phase III NVALT-11/DLCRG-02 study D De Ruysscher, AMC Dingemans, J Praag, J Belderbos, C Tissing-Tan, ... Journal of Clinical Oncology 36 (23), 2366-2377, 2018 | 128 | 2018 |
| Optimisation of fluorescence guidance during robot-assisted laparoscopic sentinel node biopsy for prostate cancer GH KleinJan, NS van den Berg, OR Brouwer, J de Jong, C Acar, EM Wit, ... European urology 66 (6), 991-998, 2014 | 115 | 2014 |
| Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes M Sobral-Leite, I Salomon, M Opdam, DT Kruger, KJ Beelen, ... Breast Cancer Research 21, 1-12, 2019 | 110 | 2019 |
| Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study … WJ Koemans, RT van der Kaaij, H Boot, T Buffart, AAFA Veenhof, ... BMC cancer 19, 1-8, 2019 | 92 | 2019 |
| Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath R De Vries, M Muller, V Van Der Noort, W Theelen, RD Schouten, ... Annals of Oncology 30 (10), 1660-1666, 2019 | 69 | 2019 |
| A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14) MMH R. C. Boshuizen, V. vd Noort, J. A. Burgers, G. J. M. Herder, S. M. S ... Lung Cancer 108, 9-14, 2017 | 59 | 2017 |
| Grading of neuroendocrine neoplasms: mitoses and Ki-67 are both essential MLF van Velthuysen, EJ Groen, V Van Der Noort, A Van De Pol, ... Neuroendocrinology 100 (2-3), 221-227, 2015 | 56 | 2015 |
| A randomized phase II study comparing paclitaxel–carboplatin–bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer … AMC Dingemans, HJM Groen, GJM Herder, JA Stigt, EF Smit, I Bahce, ... Annals of Oncology 26 (11), 2286-2293, 2015 | 54 | 2015 |
| Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with … GS Sonke, A Van Ommen-Nijhof, N Wortelboer, V van der Noort, ... Journal of Clinical Oncology 41 (17_suppl), LBA1000-LBA1000, 2023 | 53 | 2023 |
| Predictive factors for pharyngocutaneous fistulization after total laryngectomy: a Dutch Head and Neck Society audit L Lansaat, V Van Der Noort, SE Bernard, SEJ Eerenstein, BEC Plaat, ... European Archives of Oto-Rhino-Laryngology 275, 783-794, 2018 | 52 | 2018 |
| Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin A Stiekema, Q Boldingh, CM Korse, V Van Der Noort, H Boot, ... Gynecologic oncology 136 (3), 562-566, 2015 | 49 | 2015 |
| FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non‐small cell lung cancer WSME Theelen, L Mittempergher, SM Willems, AJ Bosma, DDGC Peters, ... The Journal of Pathology: Clinical Research 2 (4), 223-233, 2016 | 47 | 2016 |
| Evaluation of a hanging-breast PET system for primary tumor visualization in patients with stage I–III breast cancer: comparison with standard PET/CT SC Teixeira, JF Rebolleda, BB Koolen, J Wesseling, RS Jurado, ... American Journal of Roentgenology 206 (6), 1307-1314, 2016 | 47 | 2016 |
| Postlaryngectomy prosthetic voice rehabilitation outcomes in a consecutive cohort of 232 patients over a 13‐year period JF Petersen, L Lansaat, AJ Timmermans, V van der Noort, FJM Hilgers, ... Head & neck 41 (3), 623-631, 2019 | 45 | 2019 |
Harm van TinterenHoofd afdeling Biometrics, Antoni van Leeuwenhoek在 nki.nl 的电子邮件经过验证
